title: [Treatment of not-with cystic fibrosis associated forms bronchiectasis (non-CF bronchiectasis)].
abstract: Bronchiectasis has become more rarely because of the development of antibiotic therapy and vaccination. At present the great majority of bronchiectasis is more likely caused by congenital disorders than by infective reasons. Therapeutic strategies based on the experiences from cystic fibrosis and chronic obstructive pulmonary disease are not always conferrable to patients suffering from bronchiectasis. There are not enough controlled studies to give evidence-based recommendations in the treatment of bronchiectasis, which are not associated with cystic fibrosis. Goals in the treatment are improvement of the mucociliar clearance, the therapy of infections and treatment of inflammation. Currently several agents are under examination. To improve the prognosis and therapy options it would be reasonable to build up a national register for patients with bronchiectasis.
authors.affiliation: Abteilung Pneumologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, Hannover, Germany. Rademacher.jessica@mh-hannover.de
authors.forename: J
authors.initials: J
authors.lastname: Rademacher
authors.forename: M W
authors.initials: MW
authors.lastname: Pletz
authors.forename: T
authors.initials: T
authors.lastname: Welte
mesh_terms: D000280:Administration, Inhalation; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001987:Bronchiectasis / Q000188:drug therapy* / Q000209:etiology; D003550:Cystic Fibrosis / Q000150:complications; D024881:Drug Resistance, Bacterial; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D005100:Expectorants / Q000627:therapeutic use*; D006469:Hemoptysis / Q000209:etiology; D006801:Humans; D009079:Mucociliary Clearance / Q000187:drug effects; D011379:Prognosis
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D005100:Expectorants